{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T22:49:12Z","timestamp":1793659752214,"version":"4.5.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T00:00:00Z","timestamp":1629244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["Scientific Research (A) 26252048 and 18H03971"],"award-info":[{"award-number":["Scientific Research (A) 26252048 and 18H03971"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although a canine adenovirus (CAdV)-based oncolytic virus (OV) candidate targeting canine tumors has been reported, its oncolytic effect could be attenuated by CAdV vaccine-induced neutralizing antibodies in dog patients. To circumvent this issue, we focused on the bat adenovirus (BtAdV) strain, which was previously isolated from healthy microbats. We previously showed that this virus replicated efficiently in canine cell lines and did not serologically cross-react with CAdVs, suggesting that it may offer the possibility of an OV candidate for canine tumors. Here, we tested the growth properties and cytotoxicity of the BtAdV Mm32 strain in a panel of canine tumor cells and found that its characteristics were equivalent to those of CAdVs. To produce an Mm32 construct with enhanced tumor specificity, we established a novel reverse genetics system for BtAdV based on bacterial artificial chromosomes, and generated a recombinant virus, Mm32-E1Ap\u2009+\u2009cTERTp, by inserting a tumor-specific canine telomerase reverse transcriptase promoter into its E1A regulatory region. The growth and cytotoxicity of this recombinant were superior to those of wild-type Mm32 in canine tumor cells, unlike in normal canine cells. These data suggest that Mm32-E1Ap\u2009+\u2009cTERTp could be a promising OV for alternative canine cancer therapies.<\/jats:p>","DOI":"10.1038\/s41598-021-96101-4","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T10:14:09Z","timestamp":1629281649000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["A potential bat adenovirus-based oncolytic virus targeting canine cancers"],"prefix":"10.1038","volume":"11","author":[{"given":"Hiromichi","family":"Matsugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Kitamura-Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Kamiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroho","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Takenaka-Uema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Horimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"96101_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.prevetmed.2015.03.018","volume":"120","author":"M Inoue","year":"2015","unstructured":"Inoue, M., Hasegawa, A., Hosoi, Y. & Sugiura, K. A current life table and causes of death for insured dogs in Japan. Prev. Vet. Med. 120, 210\u2013218 (2015).","journal-title":"Prev. Vet. Med."},{"key":"96101_CR2","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1939-1676.2011.0695.x","volume":"25","author":"JM Fleming","year":"2011","unstructured":"Fleming, J. M., Creevy, K. E. & Promislow, D. E. L. Mortality in North American dogs from 1984 to 2004: An investigation into age-, size-, and breed-related causes of death. J. Vet. Intern. Med. 25, 187\u2013198 (2011).","journal-title":"J. Vet. Intern. Med."},{"key":"96101_CR3","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/j.1748-5827.2010.00974.x","volume":"51","author":"VJ Adams","year":"2010","unstructured":"Adams, V. J., Evans, K. M., Sampson, J. & Wood, J. L. N. Methods and mortality results of a health survey of purebred dogs in the UK. J. Small Anim. Pract. 51, 512\u2013524 (2010).","journal-title":"J. Small Anim. Pract."},{"key":"96101_CR4","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1080\/21645515.2020.1723363","volume":"16","author":"M Mondal","year":"2020","unstructured":"Mondal, M., Guo, J., He, P. & Zhou, D. Recent advances of oncolytic virus in cancer therapy. Hum. Vaccines Immunother. 16, 2389\u20132402 (2020).","journal-title":"Hum. Vaccines Immunother."},{"key":"96101_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/cancers10110404","volume":"10","author":"D S\u00e1nchez","year":"2018","unstructured":"S\u00e1nchez, D., Cesarman-Maus, G., Amador-Molina, A. & Lizano, M. Oncolytic viruses for canine cancer treatment. Cancers 10, 404 (2018).","journal-title":"Cancers"},{"key":"96101_CR6","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.3390\/v6052122","volume":"6","author":"I Gentschev","year":"2014","unstructured":"Gentschev, I. et al. Oncolytic virotherapy of canine and feline cancer. Viruses 6, 2122\u20132137 (2014).","journal-title":"Viruses"},{"key":"96101_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/sj.onc.1203251","volume":"19","author":"J Fueyo","year":"2000","unstructured":"Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2\u201312 (2000).","journal-title":"Oncogene"},{"key":"96101_CR8","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.3390\/v7112905","volume":"7","author":"PH Cheng","year":"2015","unstructured":"Cheng, P. H., Wechman, S. L., McMasters, K. M. & Zhou, H. S. Oncolytic replication of E1b-deleted adenoviruses. Viruses 7, 5767\u20135779 (2015).","journal-title":"Viruses"},{"key":"96101_CR9","first-page":"3181","volume":"63","author":"T Wirth","year":"2003","unstructured":"Wirth, T. et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. Cancer Res. 63, 3181\u20133188 (2003).","journal-title":"Cancer Res."},{"key":"96101_CR10","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1128\/JVI.79.2.1308-1311.2005","volume":"79","author":"VV Ternovoi","year":"2005","unstructured":"Ternovoi, V. V. et al. Productive replication of human adenovirus type 5 in canine cells. J. Virol. 79, 1308\u20131311 (2005).","journal-title":"J. Virol."},{"key":"96101_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S1525-0016(02)00049-7","volume":"7","author":"A Hemminki","year":"2003","unstructured":"Hemminki, A. et al. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol. Ther. 7, 163\u2013173 (2003).","journal-title":"Mol. Ther."},{"key":"96101_CR12","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1038\/mt.2014.7","volume":"22","author":"E Laborda","year":"2014","unstructured":"Laborda, E. et al. A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology. Mol. Ther. 22, 986\u2013998 (2014).","journal-title":"Mol. Ther."},{"key":"96101_CR13","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1089\/10430340050083289","volume":"11","author":"Y Chen","year":"2000","unstructured":"Chen, Y., Yu, D. C., Charlton, D. & Henderson, D. R. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum. Gene Ther. 11, 1553\u20131567 (2000).","journal-title":"Hum. Gene Ther."},{"key":"96101_CR14","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/mt.2016.67","volume":"24","author":"K Taipale","year":"2016","unstructured":"Taipale, K. et al. Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy. Mol. Ther. 24, 1323\u20131332 (2016).","journal-title":"Mol. Ther."},{"key":"96101_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/cgt.2010.79","volume":"18","author":"O Hemminki","year":"2011","unstructured":"Hemminki, O. et al. Oncolytic adenovirus based on serotype 3. Cancer Gene Ther. 18, 288\u2013296 (2011).","journal-title":"Cancer Gene Ther."},{"key":"96101_CR16","unstructured":"International Committee on Taxonomy of Viruses (ICTV). https:\/\/talk.ictvonline.org\/."},{"key":"96101_CR17","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1128\/JVI.02497-09","volume":"84","author":"Y Li","year":"2010","unstructured":"Li, Y. et al. Host range, prevalence, and genetic diversity of adenoviruses in bats. J. Virol. 84, 3889\u20133897 (2010).","journal-title":"J. Virol."},{"key":"96101_CR18","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1099\/jgv.0.000470","volume":"97","author":"B Tan","year":"2016","unstructured":"Tan, B. et al. Novel bat adenoviruses with an extremely large E3 gene. J. Gen. Virol. 97, 1625\u20131635 (2016).","journal-title":"J. Gen. Virol."},{"key":"96101_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/v9120371","volume":"9","author":"H Ogawa","year":"2017","unstructured":"Ogawa, H. et al. Characterization of a novel bat adenovirus isolated from straw-colored fruit bat (Eidolon helvum). Viruses 9, 371 (2017).","journal-title":"Viruses"},{"key":"96101_CR20","doi-asserted-by":"crossref","unstructured":"Hackenbrack, N. et al. Evolution and cryo-electron microscopy capsid structure of a North American bat adenovirus and its relationship to other mastadenoviruses. J. Virol. 91, e01504-16 (2017).","DOI":"10.1128\/JVI.01504-16"},{"key":"96101_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41598-018-37224-z","volume":"9","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi, T. et al. Characterization of a novel species of adenovirus from Japanese microbat and role of CXADR as its entry factor. Sci. Rep. 9, 573 (2019).","journal-title":"Sci. Rep."},{"key":"96101_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.gene.2005.05.030","volume":"358","author":"S Long","year":"2005","unstructured":"Long, S., Argyle, D. J., Gault, E. A., Campbell, S. & Nasir, L. The canine telomerase catalytic subunit (dogTERT): Characterisation of the gene promoter and identification of proximal core sequences necessary for specific transcriptional activity in canine telomerase positive cell lines. Gene 358, 111\u2013120 (2005).","journal-title":"Gene"},{"key":"96101_CR23","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1476-5810.2006.00098.x","volume":"4","author":"R Uyama","year":"2006","unstructured":"Uyama, R. et al. Establishment of four pairs of canine mammary tumour cell lines derived from primary and metastatic origin and their E-cadherin expression. Vet. Comp. Oncol. 4, 104\u2013113 (2006).","journal-title":"Vet. Comp. Oncol."},{"key":"96101_CR24","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1292\/jvms.66.1437","volume":"66","author":"K Inoue","year":"2004","unstructured":"Inoue, K. et al. Establishment and characterization of four canine melanoma cell lines. J. Vet. Med. Sci. 66, 1437\u20131440 (2004).","journal-title":"J. Vet. Med. Sci."},{"key":"96101_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1292\/jvms.63.83","volume":"63","author":"E Ohashi","year":"2001","unstructured":"Ohashi, E. et al. Effect of retinoids on growth inhibition of two canine melanoma cell lines. J. Vet. Med. Sci. 63, 83\u201386 (2001).","journal-title":"J. Vet. Med. Sci."},{"key":"96101_CR26","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1292\/jvms.61.361","volume":"61","author":"EF Barroga","year":"1999","unstructured":"Barroga, E. F., Kadosawa, T., Okumura, M. & Fujinaga, T. Establishment and characterization of the growth and pulmonary metastasis of a highly lung metastasizing cell line from canine osteosarcoma in nude mice. J. Vet. Med. Sci. 61, 361\u2013367 (1999).","journal-title":"J. Vet. Med. Sci."},{"key":"96101_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1292\/jvms.60.757","volume":"60","author":"SH Hong","year":"1998","unstructured":"Hong, S. H. et al. Establishment and characterization of two cell lines derived from canine spontaneous osteosarcoma. J. Vet. Med. Sci. 60, 757\u2013760 (1998).","journal-title":"J. Vet. Med. Sci."},{"key":"96101_CR28","first-page":"267","volume":"114","author":"M Nagase","year":"1992","unstructured":"Nagase, M. et al. Establishment and characterization of a canine mast cell line (LuMC). J. Vet. Med. Sci. 114, 267 (1992).","journal-title":"J. Vet. Med. Sci."},{"key":"96101_CR29","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1128\/JVI.00104-08","volume":"82","author":"P Pelka","year":"2008","unstructured":"Pelka, P., Ablack, J. N. G., Fonseca, G. J., Yousef, A. F. & Mymryk, J. S. Intrinsic structural disorder in adenovirus E1A: A viral molecular hub linking multiple diverse processes. J. Virol. 82, 7252\u20137263 (2008).","journal-title":"J. Virol."},{"key":"96101_CR30","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/0092-8674(79)90275-7","volume":"17","author":"N Jones","year":"1979","unstructured":"Jones, N. & Shenk, T. Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells. Cell 17, 683\u2013689 (1979).","journal-title":"Cell"},{"key":"96101_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1128\/JVI.74.1.505-512.2000","volume":"74","author":"EJ Kremer","year":"2000","unstructured":"Kremer, E. J., Boutin, S., Chillon, M. & Danos, O. Canine adenovirus vectors: An alternative for adenovirus-mediated gene transfer. J. Virol. 74, 505\u2013512 (2000).","journal-title":"J. Virol."},{"key":"96101_CR32","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1292\/jvms.61.1125","volume":"61","author":"M Yazawa","year":"1999","unstructured":"Yazawa, M. et al. Measurement of telomerase activity in dog tumors. J. Vet. Med. Sci. 61, 1125\u20131129 (1999).","journal-title":"J. Vet. Med. Sci."},{"key":"96101_CR33","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1128\/jvi.64.5.2047-2056.1990","volume":"64","author":"M Gr\u00e4ble","year":"1990","unstructured":"Gr\u00e4ble, M. & Hearing, P. Adenovirus type 5 packaging domain is composed of a repeated element that is functionally redundant. J. Virol. 64, 2047\u20132056 (1990).","journal-title":"J. Virol."},{"key":"96101_CR34","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1006\/mthe.2001.0263","volume":"3","author":"C Soudais","year":"2001","unstructured":"Soudais, C., Boutin, S. & Kremer, E. J. Characterization of cis-acting sequences involved in canine adenovirus packaging. Mol. Ther. 3, 631\u2013640 (2001).","journal-title":"Mol. Ther."},{"key":"96101_CR35","doi-asserted-by":"publisher","first-page":"26871","DOI":"10.18632\/oncotarget.15845","volume":"8","author":"T Cheng","year":"2017","unstructured":"Cheng, T. et al. A novel oncolytic adenovirus based on simian adenovirus serotype 24. Oncotarget 8, 26871\u201326885 (2017).","journal-title":"Oncotarget"},{"key":"96101_CR36","doi-asserted-by":"publisher","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn, I. et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE 3, e2409 (2008).","journal-title":"PLoS ONE"},{"key":"96101_CR37","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","volume":"13","author":"O Hemminki","year":"2020","unstructured":"Hemminki, O., Dos Santos, J. M. & Hemminki, A. Oncolytic viruses for cancer immunotherapy. J. Hematol. Oncol. 13, 84 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"96101_CR38","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.omto.2019.05.003","volume":"14","author":"M Nakatake","year":"2019","unstructured":"Nakatake, M. et al. Partial deletion of glycoprotein B5R enhances vaccinia virus neutralization escape while preserving oncolytic function. Mol. Ther. Oncolytics. 14, 159\u2013171 (2019).","journal-title":"Mol. Ther. Oncolytics."},{"key":"96101_CR39","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1158\/1535-7163.MCT-20-0134","volume":"19","author":"ES Bah","year":"2020","unstructured":"Bah, E. S., Nace, R. A., Peng, K. W., Mu\u00f1oz-Al\u00eda, M. \u00c1. & Russell, S. J. Retargeted and stealth modified oncolytic measles viruses for systemic cancer therapy in measles-immune patients. Mol. Cancer Ther. 19, 2057\u20132067 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"96101_CR40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.vaccine.2005.08.101","volume":"24","author":"DS Bangari","year":"2006","unstructured":"Bangari, D. S. & Mittal, S. K. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24, 849\u2013862 (2006).","journal-title":"Vaccine"},{"key":"96101_CR41","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","volume":"586","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature 586, 578\u2013582 (2020).","journal-title":"Nature"},{"key":"96101_CR42","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"96101_CR43","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1093\/nar\/gkv031","volume":"43","author":"M M\u00fcck-H\u00e4usl","year":"2015","unstructured":"M\u00fcck-H\u00e4usl, M., Solanki, M., Zhang, W., Ruzsics, Z. & Ehrhardt, A. Ad 2.0: A novel recombineering platform for high-throughput generation of tailored adenoviruses. Nucleic Acids Res. 43, e50 (2015).","journal-title":"Nucleic Acids Res."},{"key":"96101_CR44","doi-asserted-by":"publisher","first-page":"e40385","DOI":"10.1371\/journal.pone.0040385","volume":"7","author":"MDJ Dicks","year":"2012","unstructured":"Dicks, M. D. J. et al. A novel chimpanzee adenovirus vector with low human seroprevalence: Improved systems for vector derivation and comparative immunogenicity. PLoS ONE 7, e40385 (2012).","journal-title":"PLoS ONE"},{"key":"96101_CR45","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/v12070767","volume":"12","author":"H Matsugo","year":"2020","unstructured":"Matsugo, H. et al. Establishment of a simple and efficient reverse genetics system for canine adenoviruses using bacterial artificial chromosomes. Viruses 12, 767 (2020).","journal-title":"Viruses"},{"key":"96101_CR46","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1128\/JVI.77.2.1633-1637.2003","volume":"77","author":"M Yamamoto","year":"2003","unstructured":"Yamamoto, M., Davydova, J., Takayama, K., Alemany, R. & Curiel, D. T. Transcription initiation activity of adenovirus left-end sequence in adenovirus vectors with E1 deleted. J. Virol. 77, 1633\u20131637 (2003).","journal-title":"J. Virol."},{"key":"96101_CR47","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/sj.cgt.7700940","volume":"13","author":"M Majem","year":"2006","unstructured":"Majem, M. et al. Control of E1A under an E2F\u20131 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-\u039424RGD. Cancer Gene Ther. 13, 696\u2013705 (2006).","journal-title":"Cancer Gene Ther."},{"key":"96101_CR48","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1128\/JVI.05974-11","volume":"86","author":"C Kohl","year":"2012","unstructured":"Kohl, C. et al. Genome analysis of bat adenovirus 2: indications of interspecies transmission. J. Virol. 86, 1888\u20131892 (2012).","journal-title":"J. Virol."},{"key":"96101_CR49","doi-asserted-by":"publisher","first-page":"e73555","DOI":"10.1371\/journal.pone.0073555","volume":"8","author":"CC Hwang","year":"2013","unstructured":"Hwang, C. C. et al. Oncolytic reovirus in canine mast cell tumor. PLoS ONE 8, e73555 (2013).","journal-title":"PLoS ONE"},{"key":"96101_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/vco.12361","volume":"16","author":"CC Hwang","year":"2018","unstructured":"Hwang, C. C. et al. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours. Vet. Comp. Oncol. 16, 229\u2013238 (2018).","journal-title":"Vet. Comp. Oncol."},{"key":"96101_CR51","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1093\/nar\/gni035","volume":"33","author":"S Warming","year":"2005","unstructured":"Warming, S., Costantino, N., Court, D. L., Jenkins, N. A. & Copeland, N. G. Simple and highly efficient BAC recombineering using galK selection. Nucleic Acids Res. 33, e36 (2005).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96101-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96101-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T12:38:15Z","timestamp":1670071095000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-96101-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["96101"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-96101-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,18]]},"assertion":[{"value":"19 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16706"}}